8-K: Allurion Technologies Reports Mixed Q4 Results, Reaffirms 2024 Guidance Amidst Market Shifts

Allurion Technologies reported a decrease in fourth-quarter revenue but saw a 30% increase in procedural volume for 2023, while reiterating its 2024 financial guidance.

Summary

• Allurion Technologies announced its financial results for the fourth quarter and full year of 2023, showing a mixed performance.
• Fourth-quarter revenue was $8.2 million, a significant decrease from $19.2 million in the same period of 2022, due to macroeconomic headwinds and inventory adjustments by distributors.
• Full-year 2023 revenue reached $53.5 million, consistent with a prior announcement.
• Procedural volume, measured by new app users, increased by 30% in 2023 compared to 2022, indicating strong demand for the Allurion Program.
• The company completed enrollment in the AUDACITY pivotal trial ahead of schedule, a key step for FDA approval.
• Allurion implemented a cost reduction plan aimed at reducing cash burn to approximately $30 million in 2024.
• The company's cash and cash equivalents totaled $38 million as of December 31, 2023, an increase of $30.4 million from the previous year due to a business combination and debt paydown.
• For 2024, Allurion anticipates procedural volume growth of 20%, revenue between $60 and $65 million, and gross margins of 77-79%.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with strong procedural volume growth offset by a significant revenue decline and increased losses. The reiteration of 2024 guidance provides some optimism, but the overall sentiment is neutral to slightly negative due to the poor Q4 results.

Positives

• Procedural volume increased by 30% in 2023, demonstrating strong demand for the Allurion Program.
• The company completed enrollment in the AUDACITY pivotal trial ahead of schedule, which is a positive step towards FDA approval.
• A strategic cost reduction effort is expected to reduce cash burn to approximately $30 million in 2024.
• The company's cash position improved significantly, with cash and cash equivalents totaling $38 million as of December 31, 2023.
• Allurion is reiterating its 2024 financial guidance, indicating confidence in its future performance.

Negatives

• Fourth-quarter revenue decreased significantly to $8.2 million from $19.2 million in the same period of 2022.
• The company experienced a loss from operations of $25.7 million in the fourth quarter, compared to $10.1 million in the same period of 2022.
• General and administrative expenses increased significantly to $15.4 million in the fourth quarter, driven by accounts receivable reserves and stock-based compensation expenses.
• The company's net loss attributable to common shareholders was $19.18 million for the fourth quarter.

Risks

• Macroeconomic headwinds and inventory adjustments by distributors negatively impacted fourth-quarter revenue.
• The surge of attention paid to GLP-1 drugs may pose a competitive challenge.
• The company faces risks related to obtaining regulatory approval for and successfully commercializing the Allurion Program.
• The company's financial performance is subject to general economic, political, and business conditions.
• The company's ability to maintain its listing on the New York Stock Exchange is a risk factor.
• The company is exposed to the impact of global events such as the COVID-19 pandemic and geopolitical conflicts.

Future Outlook

Allurion anticipates 20% procedural volume growth and revenue between $60 and $65 million for 2024, with gross margins of 77-79%. The company also expects to reduce cash burn to approximately $30 million for the full year.

Management Comments

• Shantanu Gaur, Chief Executive Officer, stated that despite the impact of macroeconomic conditions and the surge of attention paid to GLP-1 drugs, the company saw strong procedural volume growth in 2023.
• Management believes the Allurion Program benefits from the heightened market attention in the weight management space and provides a comprehensive solution for obesity.

Industry Context

The announcement comes amid increased attention on weight management solutions, including GLP-1 drugs, which are impacting the market. Allurion is positioning its program as a complementary or alternative solution, leveraging the increased awareness of weight management options.

Comparison to Industry Standards

• The 30% increase in procedural volume is a positive sign, indicating strong demand for the Allurion Program, however, the decrease in revenue suggests challenges in converting demand into sales.
• The company's gross margin of 78% is relatively strong, but the significant increase in operating expenses and loss from operations is concerning.
• The company's cash burn target of $30 million for 2024 is a positive step towards financial stability, but it will need to be closely monitored.
• Compared to other medical device companies in the weight loss space, Allurion's focus on a non-surgical, swallowable gastric balloon is a unique offering, but it faces competition from both surgical and pharmaceutical options.

Stakeholder Impact

• Shareholders may be concerned about the significant decrease in fourth-quarter revenue and increased losses.
• Employees may be impacted by the strategic cost reduction efforts.
• Customers may benefit from the increased availability of the Allurion Program.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's financial performance.

Next Steps

• Allurion will continue to focus on driving procedural volume growth and increasing penetration in key markets.
• The company will continue to implement its cost reduction efforts to reduce cash burn.
• Allurion will continue to work towards obtaining FDA approval for the Allurion Balloon.
• The company will host a conference call to discuss the results.

Key Dates

Keywords

Allurion, obesity, weight loss, gastric balloon, financial results, revenue, procedural volume, cash burn, FDA, AUDACITY trial, GLP-1, virtual care, healthcare